ACADIA Pharmaceuticals (ACAD) Set to Release Earnings on Wednesday

ACADIA Pharmaceuticals (NASDAQ:ACAD) is expected to announce its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of $0.1992 per share and revenue of $332.58 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.11. The firm had revenue of $308.00 million for the quarter, compared to analyst estimates of $296.55 million. ACADIA Pharmaceuticals’s revenue for the quarter was up 16.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.16 earnings per share. On average, analysts expect ACADIA Pharmaceuticals to post $0.64 EPS for the current fiscal year and $0.98 EPS for the next fiscal year.

ACADIA Pharmaceuticals Trading Up 2.2%

Shares of NASDAQ ACAD opened at $20.17 on Wednesday. ACADIA Pharmaceuticals has a 12 month low of $18.39 and a 12 month high of $30.96. The company has a 50-day simple moving average of $24.30 and a 200-day simple moving average of $23.82.

Insider Transactions at ACADIA Pharmaceuticals

In other news, EVP Mark C. Schneyer sold 14,292 shares of the stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $29.22, for a total transaction of $417,612.24. Following the transaction, the executive vice president directly owned 67,828 shares in the company, valued at $1,981,934.16. This represents a 17.40% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Elizabeth Thompson sold 16,558 shares of the firm’s stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $26.13, for a total transaction of $432,660.54. Following the completion of the sale, the executive vice president directly owned 18,994 shares in the company, valued at $496,313.22. This represents a 46.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 36,699 shares of company stock worth $1,019,894. 26.20% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. UBS Group downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $49.00 to $23.00 in a research note on Tuesday, October 13th. Deutsche Bank Aktiengesellschaft lowered their target price on shares of ACADIA Pharmaceuticals from $38.00 to $31.00 and set a “buy” rating for the company in a research note on Friday, September 25th. Needham & Company LLC reaffirmed a “buy” rating and issued a $35.00 target price on shares of ACADIA Pharmaceuticals in a research note on Monday, October 19th. William Blair set a $33.00 price target on ACADIA Pharmaceuticals in a report on Monday, September 28th. Finally, Citizens Jmp cut their price target on ACADIA Pharmaceuticals from $36.00 to $33.00 and set a “market outperform” rating for the company in a report on Friday, September 25th. Thirteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $31.34.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system and neuropsychiatric disorders. The company’s research programs target conditions with significant unmet medical needs, including neurological and rare neurodevelopmental diseases.

ACADIA’s commercial products include NUPLAZID (pimavanserin), an atypical antipsychotic approved in the United States to treat hallucinations and delusions associated with Parkinson’s disease psychosis.